Company Filing History:
Years Active: 2024
Title: Stine Granum: Innovator in Anticancer Vaccine Development
Introduction
Stine Granum is a notable inventor based in Oslo, Norway. He has made significant contributions to the field of cancer treatment through his innovative work on therapeutic vaccines. His research focuses on developing solutions that can potentially improve patient outcomes in oncology.
Latest Patents
Stine Granum holds 1 patent for a therapeutic anticancer neoepitope vaccine. This invention relates to an anticancer vaccine that includes polynucleotides or polypeptides. The vaccine is designed to treat cancer by utilizing a polynucleotide with a nucleotide sequence that encodes a targeting unit, a dimerization unit, a first linker, and an antigenic unit. The antigenic unit consists of 3 to 50 antigenic subunits, each containing a part of a cancer neoepitope sequence. The vaccine can also include a polypeptide encoded by the polynucleotide or a dimeric protein composed of two polypeptides.
Career Highlights
Stine Granum is currently associated with Nykode Therapeutics ASA, where he continues to advance his research in therapeutic vaccines. His work is pivotal in the ongoing fight against cancer, and he is recognized for his innovative approach to vaccine development.
Collaborations
Stine collaborates with talented individuals such as Elisabeth Stubsrud and Agnete Brunsvik Fredriksen, who contribute to the success of his projects and research initiatives.
Conclusion
Stine Granum's contributions to the field of cancer treatment through his innovative vaccine development highlight the importance of research and collaboration in advancing medical science. His work exemplifies the potential of targeted therapies in improving patient care and outcomes.